Decoy Therapeutics director granted 2,000 shares
A Decoy Therapeutics director received 2,000 restricted shares that fully vest in August 2027 as part of equity compensation.
Rhea-AI Filing Summary
Decoy Therapeutics Inc. (symbol: DCOY) is the issuer of record for a Form 4 filing submitted to the SEC. Gauthier Patricia G. reported acquisition or exercise transactions in this Form 4 filing.
Decoy Therapeutics Inc. (DCOY) reported that director Patricia G. Gauthier received a grant of 2,000 shares of Common Stock on August 31, 2026. The award was granted at $0.00 per share as restricted stock under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan and 100 percent will vest on August 30, 2027. Following this grant, she directly holds 2,000 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 2,000 shares
Grant/Award
1 txn
Insider
Gauthier Patricia G.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1 | 2,000 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 2,000 shares (Direct)
Footnotes (1)
- F1. Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027.
Key Figures
Restricted stock granted: 2,000 shares
Grant price: $0.00 per share
Shares held after transaction: 2,000 shares
+1 more
4 metrics
Restricted stock granted
2,000 shares
Grant to director Patricia G. Gauthier on August 31, 2026
Grant price
$0.00 per share
Equity grant under 2026 Equity Incentive Plan
Shares held after transaction
2,000 shares
Director’s direct holdings following the August 31, 2026 grant
Vesting date
August 30, 2027
100 percent of restricted stock vests on this date
Key Terms
Restricted stock, Equity Incentive Plan, vesting
3 terms
Restricted stock financial
"Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
Equity Incentive Plan financial
"granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
vesting financial
"100 percent will vest on August 30, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What insider transaction did Decoy Therapeutics (DCOY) report for Patricia G. Gauthier?
Decoy Therapeutics reported that director Patricia G. Gauthier received a grant of 2,000 shares of Common Stock as restricted stock on August 31, 2026 under the company’s 2026 Equity Incentive Plan.
Was the Decoy Therapeutics (DCOY) Form 4 transaction made under a Rule 10b5-1 trading plan?
No. The Form 4 indicates no Rule 10b5-1 trading plan for this transaction, and the document-level checkbox affirming a 10b5-1 plan is not marked as true.
AI-generated analysis. How Rhea-AI works. Not financial advice.
